(Total Views: 398)
Posted On: 03/08/2017 7:11:47 AM
Post# of 23059
$HTBX
Acquisition brings $15.2 million CPRIT grant to fund 70-patient Phase I trial
DURHAM, N.C. , March 08, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”)
(Nasdaq:HTBX), a leader in the development of immunotherapies designed to
activate a patient’s immune system against cancer, announced that the company
has entered into a definitive agreement with the holders of 75.5% of the
outstanding capital stock of Pelican Therapeutics, Inc. (“Pelican”) to acquire
an 80% controlling interest in Pelican. Headquartered in Austin, Texas , Pelican
is a privately held immuno-oncology company focused on developing agonists to
TNFRSF25, a highly differentiated and potentially “best-in-class” T cell
costimulatory receptor.
Acquisition brings $15.2 million CPRIT grant to fund 70-patient Phase I trial
DURHAM, N.C. , March 08, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”)
(Nasdaq:HTBX), a leader in the development of immunotherapies designed to
activate a patient’s immune system against cancer, announced that the company
has entered into a definitive agreement with the holders of 75.5% of the
outstanding capital stock of Pelican Therapeutics, Inc. (“Pelican”) to acquire
an 80% controlling interest in Pelican. Headquartered in Austin, Texas , Pelican
is a privately held immuno-oncology company focused on developing agonists to
TNFRSF25, a highly differentiated and potentially “best-in-class” T cell
costimulatory receptor.
(1)
(0)
Nothing I state is intended to be a recommendation to buy or sell, opinion only. Readers are solely responsible for how they use the information.
